These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 25385173)
21. Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Bainey KR; Armstrong PW; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Zhao X; Schwamm LH; Bhatt DL Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):227-35. PubMed ID: 24569634 [TBL] [Abstract][Full Text] [Related]
22. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
23. Clinical and hemodynamic effects of renin-angiotensin system blockade in cardiac transplant recipients. Karabsheh S; Verma DR; Jain M; Stoddard G; Brunisholz K; Stehlik J; Kfoury A; Gilbert E; Bader F Am J Cardiol; 2011 Dec; 108(12):1836-9. PubMed ID: 22133132 [TBL] [Abstract][Full Text] [Related]
24. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
25. Clinical significance of circulating microRNAs as diagnostic biomarkers for coronary artery disease. Zhang L; Zhang Y; Xue S; Ding H; Wang Y; Qi H; Wang Y; Zhu W; Li P J Cell Mol Med; 2020 Jan; 24(1):1146-1150. PubMed ID: 31709737 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy. Neumann A; Napp LC; Kleeberger JA; Benecke N; Pfanne A; Haverich A; Thum T; Bara C Transplantation; 2017 Jan; 101(1):e26-e33. PubMed ID: 27653298 [TBL] [Abstract][Full Text] [Related]
27. Circulating miRNA-33: a potential biomarker in patients with coronary artery disease. Reddy LL; Shah SAV; Ponde CK; Rajani RM; Ashavaid TF Biomarkers; 2019 Feb; 24(1):36-42. PubMed ID: 30022694 [TBL] [Abstract][Full Text] [Related]
28. Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study. Wieczorek-Surdacka E; Świerszcz J; Surdacki A Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848655 [TBL] [Abstract][Full Text] [Related]
29. Levels of miR-130b-5p in peripheral blood are associated with severity of coronary artery disease. Coban N; Ozuynuk AS; Erkan AF; Guclu-Geyik F; Ekici B Mol Biol Rep; 2021 Dec; 48(12):7719-7732. PubMed ID: 34689283 [TBL] [Abstract][Full Text] [Related]
30. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease. Jia SJ; Niu PP; Cong JZ; Zhang BK; Zhao M Int Immunopharmacol; 2014 Nov; 23(1):54-9. PubMed ID: 25158302 [TBL] [Abstract][Full Text] [Related]
31. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Han SW; Won YW; Yi JH; Kim HJ Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126 [TBL] [Abstract][Full Text] [Related]
32. MiR-486 and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients. Niculescu LS; Simionescu N; Sanda GM; Carnuta MG; Stancu CS; Popescu AC; Popescu MR; Vlad A; Dimulescu DR; Simionescu M; Sima AV PLoS One; 2015; 10(10):e0140958. PubMed ID: 26485305 [TBL] [Abstract][Full Text] [Related]
33. miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. Zhou J; Shao G; Chen X; Yang X; Huang X; Peng P; Ba Y; Zhang L; Jehangir T; Bu S; Liu N; Lian J Biosci Rep; 2015 Dec; 36(1):e00295. PubMed ID: 26685009 [TBL] [Abstract][Full Text] [Related]
34. Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients. Stratz C; Nührenberg T; Fiebich BL; Amann M; Kumar A; Binder H; Hoffmann I; Valina C; Hochholzer W; Trenk D; Neumann FJ Thromb Haemost; 2014 May; 111(5):902-11. PubMed ID: 24352417 [TBL] [Abstract][Full Text] [Related]
35. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Li S; Lee C; Song J; Lu C; Liu J; Cui Y; Liang H; Cao C; Zhang F; Chen H Oncotarget; 2017 Jul; 8(29):48145-48156. PubMed ID: 28624816 [TBL] [Abstract][Full Text] [Related]
36. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. Shiraki R; Inoue N; Kobayashi S; Ejiri J; Otsui K; Honjo T; Takahashi M; Hirata K; Yokoyama M; Kawashima S Life Sci; 2006 Dec; 80(1):59-66. PubMed ID: 17045300 [TBL] [Abstract][Full Text] [Related]
37. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients. Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720 [TBL] [Abstract][Full Text] [Related]
38. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880 [TBL] [Abstract][Full Text] [Related]
39. Identification and validation of microRNAs as endogenous controls for quantitative polymerase chain reaction in plasma for stable coronary artery disease. Zhang Y; Tang W; Peng L; Tang J; Yuan Z Cardiol J; 2016; 23(6):694-703. PubMed ID: 27976798 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of the renin-angiotensin system for lowering coronary artery disease risk. Sheppard RJ; Schiffrin EL Curr Opin Pharmacol; 2013 Apr; 13(2):274-9. PubMed ID: 23523606 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]